Publications by authors named "Karen L Durrant"
Article Synopsis
- The text mentions a correction to a previously published article, identified by its DOI number.
- The correction ensures accuracy in the information presented in the original research.
- This is important for maintaining the integrity of academic literature and ensuring readers have access to reliable data.
The impact of the COVID-19 pandemic on new diagnoses of recurrent fevers and autoinflammatory diseases is largely unknown. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) PFAPA/AID Working Group aimed to investigate the impact of the COVID-19 pandemic on the number of pediatric patients evaluated for recurrent fevers and autoinflammatory diseases in North America. The absolute number of new outpatient visits and the proportion of these visits attributed to recurrent fever diagnoses during the pre-pandemic period (1 March 2019-29 February 2020) and the first year of the COVID-19 pandemic (1 March 2020-28 February 2021) were examined.
View Article and Find Full Text PDFArticle Synopsis
- IL-1 mediated systemic autoinflammatory diseases, such as CAPS and TRAPS, are rare inflammatory conditions predominantly affecting children, associated with severe symptoms and poor outcomes if left untreated.
- A multinational task force of experts created evidence-based recommendations to standardize the diagnosis, treatment, and monitoring of these diseases to improve patient care.
- The task force established key principles and specific guidelines covering diagnosis, therapy, and long-term monitoring to better manage organ damage and the overall treatment of affected patients.
Objective: Autoinflammatory type I interferonopathies, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS), stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI), and Aicardi-Goutières syndrome (AGS) are rare and clinically complex immunodysregulatory diseases. With emerging knowledge of genetic causes and targeted treatments, a Task Force was charged with the development of "points to consider" to improve diagnosis, treatment, and long-term monitoring of patients with these rare diseases.
Methods: Members of a Task Force consisting of rheumatologists, neurologists, an immunologist, geneticists, patient advocates, and an allied health care professional formulated research questions for a systematic literature review.
Objective: Autoinflammatory type I interferonopathies, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS), stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI) and Aicardi-Goutières syndrome (AGS) are rare and clinically complex immunodysregulatory diseases. With emerging knowledge of genetic causes and targeted treatments, a Task Force was charged with the development of 'points to consider' to improve diagnosis, treatment and long-term monitoring of patients with these rare diseases.
Methods: Members of a Task Force consisting of rheumatologists, neurologists, an immunologist, geneticists, patient advocates and an allied healthcare professional formulated research questions for a systematic literature review.
Background: We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine.
Methods: From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination.
Background: The impact and consequences of the COVID-19 pandemic on people with rheumatic disease are unclear. We developed the COVID-19 Global Rheumatology Alliance Patient Experience Survey to assess the effects of the COVID-19 pandemic on people with rheumatic disease worldwide.
Methods: Survey questions were developed by key stakeholder groups and disseminated worldwide through social media, websites, and patient support organisations.
Introduction: Autoinflammatory diseases can cause irreversible tissue damage due to systemic inflammation. Recently, the Autoinflammatory Disease Damage Index (ADDI) was developed. The ADDI is the first instrument to quantify damage in familial Mediterranean fever, cryopyrin-associated periodic syndromes, mevalonate kinase deficiency and tumour necrosis factor receptor-associated periodic syndrome.
View Article and Find Full Text PDFObjectives: Autoinflammatory diseases cause systemic inflammation that can result in damage to multiple organs. A validated instrument is essential to quantify damage in individual patients and to compare disease outcomes in clinical studies. Currently, there is no such tool.
View Article and Find Full Text PDFKnown and hidden sources of caffeine in drug, food, and natural products.
J Am Pharm Assoc (Wash)
August 2002
Objective: To review the pharmacology, pharmacokinetics, adverse effects, and drug interactions associated with caffeine and to raise awareness of the caffeine content of many prescription, nonprescription, and herbal drugs, beverages, and foods.
Data Sources: Articles in English retrieved through a MEDLINE search (1966-August 2000) using the terms caffeine, human, and systemic. Additional product information was obtained from manufacturers' Web sites, through direct communications with manufacturers or distributors, and via Internet searches using the AltaVista search engine and the term caffeine.